• Home
  • News
  • New research published in December from the UK Medical Cannabis Registry

New research published in December from the UK Medical Cannabis Registry

At Sapphire Clinics, one of our founding principles is to ensure that we are adding to the research base that is available on medical cannabis, one of the key barriers to NHS access.

We are happy to share 4 new condition-specific research publications with you from the UK Medical Cannabis Registry that our researchers at Sapphire have been working hard on.

Those enrolled on the UK Medical Cannabis Registry have helped us with the following pieces of research: Post-Traumatic Stress Disorder, Inflammatory Bowel Disease, Depression and Children with Treatment-Resistant Epilepsy.

The aim of the UK Medical Cannabis Registry is to expand our understanding of medical cannabis in the UK by collecting and analysing clinical data. The Registry ensures that medical cannabis prescribing is evaluated in a responsible way, capturing essential data including prescribed formulations, adverse events, and patient-reported outcome measures. Data is collected from patients who consent via the Curaleaf Access Scheme. You can learn more about the Curaleaf Access Scheme here.

We would like to extend thanks to all who are signed up to the Curaleaf Access Scheme without whom this research would not be possible.

Share this article
X
Facebook
WhatsApp
LinkedIn
Email

Am I eligible?

We aim to make things easy and to keep you informed of your progress every step of the way, from the moment you apply to the receipt of your prescription(s).
Related Articles
Research
13/06/2025

Understanding how to manage pain is a key concern for many people living with sickle cell disease. At ...

Read more
News
06/06/2025

A new report from the London Drugs Commission recommends a big change for cannabis laws in the UK: ...

Read more
Blog, News
02/06/2025

Every year, Men’s Health Week serves as a crucial reminder to pause and reflect on the health challenges ...

Read more